TRACER Developmental Research Program

TRACER发展研究计划

• 批准号: 10290166
• 负责人: VICTORIA L. SEEWALDT
• 金额: $ 17.23万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10290166
• 关键词: Academic Medical Centers; Address; African American; Air Pollution; Asians; Basic Science; Behavioral; Behavioral Research; California; Cancer Center; Catchment Area; Center for Translational Science Activities; Characteristics; Cities; City of Hope Comprehensive Cancer Center; Clinical Treatment; Clinical Trials; Collaborations; Communities; Community based prevention; Core Facility; Country; Data; Development; Diagnostic; Ensure; Epidemiology; Ethnic Origin; Evaluation; Face; Financial Support; Fostering; Funding; Future; Geography; Goals; Grant; Hispanics; Human; Individual; Institution; Intervention; Latinx; Leadership; Los Angeles; Malignant neoplasm of lung; Medical; Monitor; National Cancer Institute; Outcomes Research; Pilot Projects; Population; Population Heterogeneity; Poverty; Process; Program Research Project Grants; Race; Reporting; Research; Research Personnel; Research Project Grants; Resources; Rural; Sampling; Shapes; Site; Smoking; South Carolina; Translating; Translational Research; Universities; Virginia; Woman; black men; cancer health disparity; epidemiology study; health disparity; innovation; men; non-smoking; preventive intervention; programs; racial and ethnic; rural area; success; urban area

DEVELOPMENTAL RESEARCH PROGRAM: PROJECT SUMMARY The Developmental Research Program (DRP) within this P20 Translational Research Center in Lung Cancer Disparities (TRACER) application aims to select and support highly promising and innovative pilot research projects to reduce health disparities in lung cancer. The TRACER MPI and DRP leadership (representing the 3 participating National Cancer Institute-designated cancer centers at Virginia Commonwealth University, Medical University of South Carolina, and City of Hope) have set clear priorities for the selection of pilot research projects. These priorities are (1) projects demonstrating exceptional translational science potential, (2) projects inclusive of vertical and horizontal collaborations between the 3 participating institutions, and (3) projects with maximum impact on the diverse communities serving—Virginia, South Carolina, and southern California. These pilot research projects may include basic research explorations using human samples, diagnostic or treatment clinical interventions in the form of clinical trials, or community-based prevention interventions. A major advantage of this 3-institution P20 TRACER collaborative is that it provides immediate access to distinct urban and rural regions with vastly different racial/ethnic compositions as well as cultural and environmental characteristics that likely contribute to the disparities reported in lung cancer (e.g., large African American/Black populations in Virginia and South Carolina and large Hispanic/LatinX and Asian populations in southern California, high rates of smoking in Virginia and South Carolina; high levels of air pollution in southern California). The DRP will provide direct and significant financial support for competitively selected pilot research projects and will provide these pilot project PIs or investigative teams with access to the expertise and resources of the TRACER-supported cores and an extraordinary list of other cutting-edge resources available within the 3 participating institutions. The leaders of the DRP will select and fund a minimum of 3 pilot research projects annually, and the projects’ progress will be carefully monitored by multi-levels of internal and external scientific and community advisors. The ultimate goal of the DRP is to establish a pipeline of research focused on the multi-dimensional causes of lung cancer disparities within the diverse populations served by the partnering institutions and to develop the preliminary data to support competitive research projects for a future, collaborative P50 SPORE application.

发展研究计划：项目总结 该P20肺癌翻译研究中心的发展研究计划(DRP) 差异(示踪剂)应用旨在选择和支持极具前景和创新性的先导研究 旨在减少肺癌患者健康差距的项目。跟踪MPI和DRP领导层(代表3个 参与国家癌症研究所-弗吉尼亚联邦大学指定的癌症中心，医学 南卡罗来纳大学和希望之城)为试点研究项目的选择设定了明确的优先事项。 这些优先事项是(1)显示出非凡的翻译科学潜力的项目，(2)包括在内的项目 3个参与机构之间的纵向和横向合作，以及(3)最高 对服务于弗吉尼亚州、南卡罗来纳州和南加州的不同社区的影响。这些飞行员 研究项目可能包括使用人体样本的基础研究探索、临床诊断或治疗 以临床试验或以社区为基础的预防干预措施。的一个主要优势 这种由3个机构组成的P20跟踪协作是，它提供了对不同的城市和农村的即时访问 种族/民族构成差异很大的地区以及文化和环境特征 可能导致报告的肺癌差异(例如， 弗吉尼亚州和南卡罗来纳州以及南加州的大量西班牙裔/拉丁裔和亚裔人口，比率很高 弗吉尼亚州和南卡罗来纳州吸烟人数增加；南加州空气污染水平较高)。DRP将提供 为竞争性选定的试点研究项目提供直接和重大的财政支持，并将提供 能够获得示踪剂支持的专门知识和资源的试点项目绩效指标或调查小组 核心资源和3个参与机构内可利用的其他尖端资源的特别清单。 DRP的领导人将每年至少选择和资助3个试点研究项目，这些项目的 将由多层次的内部和外部科学和社区顾问仔细监测进展情况。 DRP的最终目标是建立一个研究管道，专注于糖尿病的多维原因 合作机构服务的不同人群中肺癌的差异，并制定 初步数据，以支持未来的竞争性研究项目，合作P50孢子应用。